{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-103098","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.617323+00:00","generated_at":"2026-05-31T06:26:19.630867+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA accepts Axsome's NDA resubmission for AXS-07 migraine treatment; PDUFA date Jan 31, 2025","bullets":["FDA acknowledged Class 2 resubmission of NDA for AXS-07 for acute migraine treatment.","PDUFA goal date set for January 31, 2025.","AXS-07 is a novel oral drug candidate for acute migraine."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-103098","json":"https://secwatch.observer/filing/0000950170-24-103098.json","markdown":"https://secwatch.observer/filing/0000950170-24-103098.md","text":"https://secwatch.observer/filing/0000950170-24-103098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024103098/0000950170-24-103098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024103098/axsm-20240904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:26:19.630867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}